Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07278336 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
A Phase 1 study of Ovarian Cancer, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 207
- Enrollment target
- 8
- Study locations
NCT07278336 is a Phase 1 study of Ovarian Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 207 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (72% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT07278336, a Phase 1 study of Ovarian Cancer, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 207 participants
- Enrollment target
- 8
- Study locations
Study Summary
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with bevacizumab, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 4 Parts (Arms) where participants will receive ABBV-901, alone or in combination with the standard available therapy, bevacizumab. Around 207 participants will be enrolled in the study at approximately 75 sites around the world. In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901, alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901, combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901, combination with IV bevacizumab. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG ABBV-901
Study Locations (8)
Other
- Rambam Health Care Campus /ID# 278418 - Haifa
- Hadassah Medical Center-Hebrew University /ID# 278420 - Jerusalem
Texas
- NEXT Oncology - San Antonio /ID# 278606 - San Antonio
Utah
- Start Mountain Region /ID# 278609 - West Valley City
Virginia
- Next Virginia /ID# 278607 - Fairfax
Tel Aviv
- The Chaim Sheba Medical Center /ID# 278416 - Ramat Gan
Saitama
- Saitama Medical University International Medical Center /ID# 278437 - Hidaka
Shizuoka
- Shizuoka Cancer Center /ID# 278538 - Sunto-gun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2025-11-27 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07278336
The ClinicalTrials.gov registry entry for NCT07278336 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (72% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT07278336 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT07278336 about?
NCT07278336 is a clinical study titled "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer". Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with bevacizumab, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has...
What is the current status of trial NCT07278336?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 207 participants. The study started on 2025-11-27. Estimated completion is 2029-01.
What conditions does trial NCT07278336 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT07278336?
The interventions under investigation include: Bevacizumab (DRUG), ABBV-901 (DRUG).
Who is sponsoring clinical trial NCT07278336?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07278336 being conducted?
This trial has 8 study locations across Texas, Utah, Virginia, Tel Aviv, Saitama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.